Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

YGION Biomedical

Request full access

Develops individualized neoantigen-based cancer vaccines for personalized cancer treatment

Vienna, AustriaFounded 2022Biotech & Life Sciences

About YGION Biomedical

Based in Vienna, Austria, YGION Biomedical GmbH is a preclinical-stage biopharmaceutical company established in 2022. The firm was founded by a team of experienced biotech veterans and entrepreneurs with the objective of developing individualized immunotherapies for cancer treatment. The leadership team includes co-founders Dr. Wolfgang Fischl as Chief Executive Officer and Dr. Georg Casari as Chief Operating Officer.

YGION is focused on creating personalized "plug-and-play" cancer vaccines designed to activate a patient's own immune system to fight the disease. The company's business model revolves around the research and development of these bespoke therapies, with a strategy that involves securing funding to advance its programs through preclinical and clinical trials. A significant milestone was achieved in May 2024, when YGION secured €15 million ($16.1M) in a Series A financing round from an Austrian private trust. This capital is being used to further the development of its core technology and lead program.

The company's central product is its proprietary YGNITE™ technology platform, which is engineered to produce neoepitope peptide vaccines tailored to each patient's specific tumor. This platform integrates three core areas: advanced next-generation sequencing (NGS) for detailed analysis of tumor and healthy tissue; an in-house bioinformatics platform to identify and select key neoepitopes; and the proprietary CARGONAUT™ immune-modulating carrier system. The CARGONAUT™ system links to the synthesized neoepitopes and delivers them to the patient's antigen-presenting cells, inducing a precise and powerful tumor-specific immune response. YGION's lead program, YG-01, is currently in the preclinical development stage, with the recent funding aimed at moving it towards clinical validation.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
Vienna, Austria
Employees
16
Open positions
None listed
Dealroom signal
81.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2024 $17M $66M Undisclosed ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

YGION Biomedical website traffic

Latest recorded traffic for YGION Biomedical is 980 monthly website visits, down 30% over the last three months. YGION Biomedical's team grew 23.1% over the past year.

Latest monthly visits980 3-month web change-30% 1-year team growth+23.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

YGION Biomedical in the Vienna ecosystem

Live from Dealroom

The YGION Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇦🇹 Austria71.4%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about YGION Biomedical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See YGION Biomedical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.